Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Incidence of Generalized myasthenia gravis
7 evidence topics · 7 sources
United States, 2021 claims and electronic health records: incidence of all myasthenia gravis
“Data were extracted from the Clarivate Real-World Data Repository (2016-2021), a US claims and electronic health records database.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The diagnosed prevalence and incidence of MG in the United States in 2021 were calculated to be 37.0 per 100,000 persons and 3.1 per 100,000 persons, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“While the incidence and prevalence of MG increased with age in both men and women, higher prevalence and incidence of MG were observed in younger women (<50 years) compared with men of matching age, and in older men (≥65 years) compared with women of the same age group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States, 2017 commercial, Medicare, and Medicaid claims: incidence of all myasthenia gravis
“From the US commercially/Medicare-insured cohort, we calculated an age-and sex-standardized incidence of 68.5 new cases per million person-years with an adjusted prevalence of 316.4 per million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within the Medicaid-insured population, similar yet slightly lower numbers emerged: the adjusted incidence was 49.7 new cases per million person-years, and the adjusted prevalence rate was 203.7 cases per million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We extrapolated this to calculate the overall US prevalence of 320.2 per million people and an incidence of 54 per million person-years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States, Medicare fee-for-service beneficiaries aged 65 years and older: incidence of all myasthenia gravis, 2008 to 2019
“Study-eligible beneficiaries were aged 65 years and older, had at least 1 month of FFS Part A/B coverage, and were without any health maintenance organization insurance coverage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MG incidence increased from 12.2 to 13.3 per 100,000 PYs from 2008–2009 to 2018–2019 (p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Taiwan, 2009 to 2019: incidence of generalized myasthenia gravis
“There was no temporal trend in all-cause fatality rates (range 2.76–3.79/100 patients annually) or gMG incidence rates (2.4–3.17/100,000 population annually).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 2019, the annual prevalence of gMG was 11.18 per 100,000 population and the incidence rate was 2.95 per 100,000 population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Canada, Ontario, 2013 to 2020: incidence of all myasthenia gravis
Global systematic review of studies through February 2024: incidence of all myasthenia gravis
“Incidence rates ranged from 2.3 to 61.3 cases per million person-years, with a mean incidence of 15.7 (95% CI: 11.5–19.9) and a median of 13.3 cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Studies showed increasing rates over the years (Fig. 4): considering the period 1967–2007, the mean IR was 8.7 (95% CI: 5.5–11.9; range: 2.3–21.3) cases per million person-years, and in the period 2008–2022, the mean IR has more than doubled: 22.9 (95% CI: 14.1–31.7; range: 6.3–61.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The American countries showed the highest mean IR cases per million person-years with a value of 23.7 (95% CI: 6.5–40.9; range: 4.7–61.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global systematic review of studies from 1950 to 2007: pooled incidence of all and AChR antibody-positive myasthenia gravis
“55 studies performed between 1950 and 2007 were included, representing 1.7 billion population-years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IR ranged from 1.7 to 21.3 cases per million person-years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled estimate IR (eIR) was calculated as 5.3 per million person-years (C.I.: 4.41 - 6.12).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AChR MG IR ranged from 4.3 to 18.0 per million person-years with a pooled AChR MG eIR of 7.3 per million person-years (C.I.: 5.5, 7.8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote